The KYAT1 antibody is a tool used to detect kynurenine aminotransferase 1 (KYAT1), also known as cysteine conjugate beta-lyase 1 (CCBL1) or KAT III. This enzyme plays a critical role in the kynurenine pathway, a major route for tryptophan catabolism, which generates metabolites involved in neuroinflammation, immune regulation, and oxidative stress. KYAT1 specifically catalyzes the transamination of kynurenine to produce kynurenic acid (KYNA), a neuroactive compound with antioxidant and neuroprotective properties. Dysregulation of KYAT1 expression or activity has been implicated in neurological disorders (e.g., Alzheimer’s disease, schizophrenia), cancer, and inflammatory conditions. The KYAT1 antibody enables researchers to study protein localization, expression levels, and functional interactions in tissues or cell lines. It is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Commercially available KYAT1 antibodies are typically validated for specificity and sensitivity across human, mouse, and rat models. Recent studies leveraging this antibody have explored its role in modulating cellular redox balance, influencing tumor microenvironments, and impacting neurotransmitter signaling. Understanding KYAT1's mechanisms could inform therapeutic strategies targeting metabolic disorders or neurodegenerative diseases linked to kynurenine pathway imbalances.